Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
Cole CB, Morelli MP, Fantini M, Miettinen M, Fetsch P, Peer C, Figg WD, Yin T, Houston N, McCoy A, Lipkowitz S, Zimmer A, Lee JM, Pavelova M, Villanueva EN, Trewhitt K, Solarz BB, Fergusson M, Mavroukakis SA, Zaki A, Tsang KY, Arlen PM, Annunziata CM.
Cole CB, et al. Among authors: figg wd.
J Exp Clin Cancer Res. 2023 Apr 26;42(1):102. doi: 10.1186/s13046-023-02668-3.
J Exp Clin Cancer Res. 2023.
PMID: 37101182
Free PMC article.
No abstract available.